Minimally-invasive versus open surgery for gastric cancer - cross-sectional analysis

Improved NCCN guideline compliance and textbook oncological outcomes among patients undergoing minimally invasive surgery for locally advanced gastric cancer – cross-sectional analysis of national cancer database

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN53410429

Enrollment

13885

Registered

2023-08-29

Start date

2013-01-01

Completion date

Unknown

Last updated

2024-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer Cancer

Interventions

In this cross-sectional study patients with stage II/III gastric cancer (cT2-T4N0-3M0) who underwent curative-intent treatment between 2013-2019 were evaluated from National Cancer Database (NCDB). Mu

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with stage II/III LAGC (cT2-T4N0-3M0) who underwent curative-intent treatment between 2013 and 2019 evaluated from the National Cancer Database (NCDB)

Exclusion criteria

Exclusion criteria: 1. Did not undergo resection 2. Metastatic (cM1) or early (cT1) GC 3. Underwent palliative care 4. Did not receive or died before planned multimodal treatment 5. Had missing information

Design outcomes

Primary

Measure	Time frame
1. National Comprehensive Cancer Network (NCCN) guideline adherence, defined as receipt of stage-specific curative intent treatment (yes/no). For systemic treatment, patients were classified as receiving guideline-adherent care if any perioperative adjunctive therapy (single- or multiagent) was administered (yes/no). For surgical treatment, patients were classified as receiving guideline-adherent care if the primary surgical procedure included evaluation of at least 15 lymph nodes (yes/no), 2. Textbook oncological outcome (TOO) The TOO definition consisted of chemotherapy receipt, (yes/no) adequate gastric resection to achieve negative resection margins (R0) (yes/no), examination of at least 15 lymph nodes (yes/no), followed by no prolonged length of hospital stay (yes/no), no 30-day mortality (yes/no), and no 30-day readmission (yes/no) Data collected from the National Cancer Database (NCDB) for patients with stage II/III gastric cancer (cT2-T4N0-3M0) who underwent curative-intent treatment between 2013-2019	—

Measure

Time frame

1. National Comprehensive Cancer Network (NCCN) guideline adherence, defined as receipt of stage-specific curative intent treatment (yes/no). For systemic treatment, patients were classified as receiving guideline-adherent care if any perioperative adjunctive therapy (single- or multiagent) was administered (yes/no). For surgical treatment, patients were classified as receiving guideline-adherent care if the primary surgical procedure included evaluation of at least 15 lymph nodes (yes/no), 2. Textbook oncological outcome (TOO) The TOO definition consisted of chemotherapy receipt, (yes/no) adequate gastric resection to achieve negative resection margins (R0) (yes/no), examination of at least 15 lymph nodes (yes/no), followed by no prolonged length of hospital stay (yes/no), no 30-day mortality (yes/no), and no 30-day readmission (yes/no) Data collected from the National Cancer Database (NCDB) for patients with stage II/III gastric cancer (cT2-T4N0-3M0) who underwent curative-intent treatment between 2013-2019

—

Secondary

Measure	Time frame
Overall survival, collected from the National Cancer Database (NCDB) for patients with stage II/III gastric cancer (cT2-T4N0-3M0) who underwent curative-intent treatment between 2013-2019	—

Countries

United States of America

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 9, 2026